Evidence map›Paper›PMID 40019627›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy.

Chikara Kunisaki, Sho Sato, Kohei Kasahara, Tsutomu Sato, Akikazu Yago, Yuko Tamura, Hiroki Kondo, Masanori Oshi, Takashi Kosaka, Hirotoshi Akiyama and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chikara KunisakiDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan. s0714@yokohama-cu.ac.jp.ORCID 0000-0002-0843-8766
Sho SatoDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Kohei KasaharaDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Tsutomu SatoDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Akikazu YagoDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Yuko TamuraDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Hiroki KondoDepartment of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-chi, Minami-ku, Yokohama, 232-0024, Japan.
Masanori OshiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan, 236-0004.
Takashi KosakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan, 236-0004.
Hirotoshi AkiyamaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan, 236-0004.
Itaru EndoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan, 236-0004.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies have focussed on using histological phenotype to evaluate prognostic factors after adjuvant chemotherapy (AC) in patients with pStage II/III gastric cancer. We evaluated the impact of histological type based on the World Health Organization classification.

methodsOverall, 348 patients with pStage II/III advanced gastric cancer undergoing R0 gastrectomy without neoadjuvant chemotherapy were included. Of these, 143 underwent AC. Univariate and multivariate analyses for prognostic factors of relapse-free survival (RFS) and overall survival (OS) were performed in all patients and patients receiving AC. Moreover, long-term survivals were compared by histological phenotype between patients with and without AC.

resultsMultivariate analysis in all patients revealed that histologically poorly cohesive carcinoma with not otherwise specified and signet ring cell subtype (PCC-NOS/SRC) and pN 2/3 independently and adversely affected RFS. Alternatively, male sex, poor PS and pN 2/3 adversely affected OS. In multivariate analysis of patients receiving AC, longer tumour size (≥ 80 mm), histologically PCC-NOS/SRC phenotype and pN 3 independently influenced RFS. Multivariate analysis in this population for OS revealed that pN 3 and poor postoperative immune-nutritional status significantly induced worse OS. Comparison of RFS and OS by histological phenotype between patients with and without AC showed that AC had no efficacy for improving long-term survivals in histologically PCC phenotype.

conclusionsHistologically PCC phenotype by WHO classification, particularly PCC-NOS/SRC phenotypes, showed poor long-term RFS even after AC in patients with pStage II and III gastric cancer. An effective chemotherapeutic regimen needs to be developed for this specific subtype of gastric cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Signet Ring CellStomach NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesGastrectomyHumansMaleMiddle AgedNeoplasm StagingPhenotypePrognosisRetrospective StudiesAdjuvant chemotherapyAdvanced gastric carcinomaHistological phenotypePoorly cohesive gastric carcinomaPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.